In preclinical models, blocking the extracellular region of Notch1 with antibodies decreased T-ALL tumor growth by inhibiting cancer cell growth and by disrupting angiogenesis (190, 191). Here, NOTCH1 is linked to acute lymphoblastic leukemia.